Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Georg et al

Published: 20 December 2021| Version 3 | DOI: 10.17632/9sw3trkv8p.3
Philipp Georg,
Rosario Astaburuaga,
Lorenzo Bonaguro,
Birgit Sawitzki


In addition to the Figures published in the original article and associated supplemental Figures, the attached files contain the following information: Mendeley Data 1-4 • Members of the PA-COVID-19 Study group • Mendeley Data 1: a reanalysis of a published scRNA-seq data set of bronchoalveolar lavage (BAL) samples from COVID-19 patients and patients with non-COVID-19 pneumonia (Wauters et al., 2021) to investigate T cells and their phenotypes from the lung . • Mendeley Data 2: Gating strategy and represantative plots of Figure S1 • Mendeley Data 3: Gating strategy and represantative plots of Figure 5D • Mendeley Data 4: Gating strategy Firgures 5F/G/H Supplementary Tables 1-6 • Supplementary Table 1: Cohort details related to Figures 1-6. • Supplementary Table 2: Gene lists for the signatures “Response to Type I Interferon” , “Defense Response to virus” and “Cytotoxicity” used for GSEA, related to Figure 2 and Figure S3. • Supplementary Table 3: Antibody panel “MCFC cohort 2” , related to Figure S1 and STAR Methods • Supplementary Table 4: Antibody panel “degranulation assays” , related to Figures 3C-E. • Supplementary Table 5: Antibody panel for “C3a binding capacity” , related to Figure 5D. • Supplementary Table 6: Antibody panel “SARS-CoV-2 reactivity” , related to Figure 3F. Gene list Annotation for scRNA sequencing



Immunology, Complement System, Immunopathology, Severe Acute Respiratory Syndrome Coronavirus 2